About
Liliumtx develops in vivo gene therapies that selectively target pathogenic T cells to treat autoimmune diseases and oncology, using engineered delivery vehicles for precise immune reprogramming.
Explore Liliumtx's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.